Rising Incidence and High Relapse Rates Drive the Global Acute Myeloid Leukemia (AML) Therapeutics Market, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Acute Myeloid Leukemia (AML) Therapeutics markets. The global market for Acute Myeloid Leukemia (AML) Therapeutics is projected to reach US$243 million by the year 2017, primarily driven by the rising incidence level, growing aging population, high level of unmet needs, increased relapse rates, and strong drug pipeline. Growth in the market is also expected to stem from the increasing number of drugs being accorded orphan drug and fast track designation by the regulatory authorities, such as the US FDA and EMEA.

Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report

Follow us on LinkedIn – Acute Myeloid Leukemia (AML) is identified as a rapidly progressing disease, associated with the elderly. Presently, approved drugs available for the treatment of AML include chemotherapy drugs such as cytarabine, anthracycline, daunorubicin, and mitoxantrone. These therapies, however, are marred with various negative factors such as low cure rates, major side effects such as neutropenia, and high relapse rates. Although other treatment options, such as bone marrow transplant offers comparatively better result, it is however not an effective option for most of the elderly patients due to its high toxicity and dearth of appropriate donors for the procedure. Therefore, the AML market is presently characterized by high unmet needs in terms of drug safety and efficacy presenting increased opportunities for new drugs with improved safety and efficacy profiles.

Over the years, the acute myeloid leukemia (AML) market has witnessed promising targeted drugs failing clinical trials, leading to the slowing down of growth prospects in the AML therapeutics scenario. Some of the promising targeted agents which have failed to improve outcomes in clinical trials include zosuquidar (P-glycoprotein modulator), sulfonylhydrazine alkylator laromustine, and Mylotarg (gemtuzumab ozogamicin). However, innovative new target agents are under various stages of clinical trials, which are expected to showcase promising results in the years to come. Also, AML therapeutic market, in recent years, has witnessed a surge in research and development activities centered on developing molecular targets, which target cell death (apoptosis) and cell cycling, apart from developing novel agents, which target DNA replication and repair. Other approaches which are being developed include immunotherapy and epigenetic based targeting. However, some of these approaches are still in their nascent stages of development, while others are exhibiting promising outcomes. In the upcoming years, the outcome of AML therapeutics are expected to be geared towards developing treatments which are less toxic and potentially safe for the elderly population, when compared to the traditional drugs.

One of the major drivers for the global AML market is the aging population worldwide. Since the incidence of AML significantly increases in the age group of 50 years and above, the aging population therefore forms a major portion of the population seeking treatment for AML. Strong growth for AML therapeutics emanates from developed regions, which have higher percentage of population in the 65+ age group, when compared to the developing countries. Developed markets, such as Europe, the US, and Japan, therefore account for a significant portion of the AML therapeutics market, when compared to the developing economies. While the present treatment of AML for elderly patients remain unimpressive, future strategies adopted by drug developers however are geared towards developing novel target based agents.

As stated by the new market research report on Acute Myeloid Leukemia Therapeutics, the US represents the largest and the fastest growing regional market worldwide. After the US, Europe forms the second largest market for AML therapeutics. Vidaza from Celgene Corp., and Ceplene from Epicept are the major AML drugs in Europe.

Given the fact that leukemia is a relatively smaller market (accounting for a meager 1% of the total cancer cases), and the development of drug in this area proving to be less lucrative for developers, there has been a dearth of investments in AML market over the years. However, various regulatory authorities such as the US FDA and European Medicines Agency (EMA) have taken up initiatives to incite interest among pharmaceutical companies to develop innovative therapies targeting AML. One such initiative taken by the regulators is awarding of orphan drug status and fast track designations or both for drugs that are being developed for AML. The move is expected to provide the much needed impetus to the market, as developers can reap benefits on investment faster, with drug hitting the markets at a faster pace and also gaining from the exclusivity benefit of the drug for a longer time period. Furthermore, with high relapse rates, the goal of treatment for AML is centered upon developing therapies, which aid in prolonged remission. Also, Stem cell transplantation, which hitherto has limited therapeutic application in AML market, are expected to become much more refined, thereby improving the scope of stem cell transplantation, particularly for use in low-intensity procedure for the elderly.

Major players in the market include Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bio-Path Holdings Inc., BioSante Pharmaceuticals Inc., Celator Pharmaceuticals Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals Inc., EpiCept Corp., Genzyme Corp., Lorus Therapeutics Inc., Novartis AG, Onconova Therapeutics Inc., Sunesis Pharmaceuticals Inc., among others.

The research report titled “Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the AML market, the present treatment options, molecular profile of presently approved drugs, the unmet medical needs, key growth drivers, market challenges, pipeline analysis including late-stage drug pipeline, recent FDA and EMAE approvals, drugs obtaining fast track and orphan drug designations, failed drugs, clinical trials, mergers and acquisitions, other strategic corporate deals, and profiles of major and niche key players globally and across different regions. The report provides annual sales estimates and projections for AML Therapeutics market in US$ Million for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Acute_Myeloid_Leukemia_AML_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website